Processa Pharmaceuticals (PCSA) Current Deferred Revenue (2014 - 2015)
Processa Pharmaceuticals' (PCSA) quarterly Current Deferred Revenue came in at $22500.0 in Q3 2015, down 86.42% on a QoQ basis from $165629.0 in Q2 2015.
Processa Pharmaceuticals (PCSA) Current Deferred Revenue (2014 - 2015) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 2 years of Current Deferred Revenue data on file, last reported at $22500.0 in Q3 2015.
- Quarterly Current Deferred Revenue changed N/A year-over-year to $22500.0 in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $22500.0 (changed N/A YoY) and the FY2014 annual result came in at $58165.0, changed N/A from the prior year.
- Current Deferred Revenue eased to $22500.0 in Q3 2015, from $165629.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $165629.0 in Q2 2015 to a low of $22500.0 in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Processa Pharmaceuticals | 5.78 Mn | 5.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 22,500.00 |
| Jun 30, 2015 | 165,629.00 |
| Mar 31, 2015 | 143,129.00 |
| Dec 31, 2014 | 58,165.00 |